Dianthus Therapeutics, Inc.
NASDAQ: DNTH0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Marino Garcia
- Employees
- 92
- Headquarters
- New York, United States
- IPO year
- 2018
- Market cap
- $3.8B
- Website
- https://dianthustx.com
Loading DNTH…
Loading profile data…Frequently asked questions about DNTH
What does Dianthus Therapeutics, Inc. (DNTH) do?
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; an...
Where does DNTH trade?
Dianthus Therapeutics, Inc. (DNTH) trades on the NASDAQ.
What sector is DNTH in?
Dianthus Therapeutics, Inc. (DNTH) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Dianthus Therapeutics, Inc.?
Marino Garcia is the chief executive officer of Dianthus Therapeutics, Inc. (DNTH).
Where is Dianthus Therapeutics, Inc. headquartered?
Dianthus Therapeutics, Inc. is headquartered in United States.
Does DNTH pay a dividend?
Dianthus Therapeutics, Inc. (DNTH) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DNTH go public?
Dianthus Therapeutics, Inc. (DNTH) completed its initial public offering in 2018.